Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01705106 · ClinicalTrials.gov registry record · Phase 1
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
A Phase 1 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01705106 is a Phase 1 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 21 participants.
The verdict
NCT01705106, a Phase 1 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This clinical trial studies capecitabine and celecoxib in treating patients with solid malignancies that are metastatic or cannot be removed by surgery. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving capecitabine and celecoxib together may be an effective treatment for solid malignancies.
Interventions
- OTHER laboratory biomarker analysis
- DRUG capecitabine
- OTHER pharmacological study
- OTHER pharmacogenomic studies
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-08-29 |
| Est. Completion | 2016-02-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01705106
The ClinicalTrials.gov registry entry for NCT01705106 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01705106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01705106 about?
NCT01705106 is a clinical study titled "Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies". This clinical trial studies capecitabine and celecoxib in treating patients with solid malignancies that are metastatic or cannot be removed by surgery. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopp...
What is the current status of trial NCT01705106?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2012-08-29. Estimated completion is 2016-02-10.
What interventions are being tested in trial NCT01705106?
The interventions under investigation include: laboratory biomarker analysis (OTHER), capecitabine (DRUG), pharmacological study (OTHER), pharmacogenomic studies (OTHER), celecoxib (DRUG).
Who is sponsoring clinical trial NCT01705106?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.